MacroGenics
MGNX
133 hedge funds and large institutions have $467M invested in MacroGenics in 2018 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 36 reducing their positions, and 16 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 36
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
2% more funds holding
Funds holding: 130 → 133 (+3)
0.04% less ownership
Funds ownership: 87.1% → 87.05% (-0.04%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
41% less capital invested
Capital invested by funds: $789M → $467M (-$322M)
78% less call options, than puts
Call options by funds: $17K | Put options by funds: $79K
Top Buyers
| 1 |
O
OppenheimerFunds
New York
|
+$6.02M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$5.75M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$5.58M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$4.91M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.71M |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$31.8M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$12.2M |
| 3 |
AH
Aviva Holdings
New Providence,
Bahamas
|
-$11.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.35M |
MGNX Hedge Fund Activity: Q4 2018 in Review
133 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q4 2018, worth a combined $467M — down 41% from $789M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new MGNX positions and 16 closed out — a net gain of 3 holders — while 57 added to existing stakes and 36 trimmed.
The largest buyer was OppenheimerFunds, adding an estimated $6.02M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $31.8M sold.
- 133 institutional investors held MacroGenics (MGNX) as of Q4 2018, up from 130 in Q3 2018.
- Funds reported $467M of MacroGenics stock for Q4 2018, down 41% quarter-over-quarter.
- 19 funds opened new MacroGenics positions in Q4 2018 and 16 closed out, a net change of +3 holders.
- The largest MacroGenics buyer in Q4 2018 was OppenheimerFunds, an estimated $6.02M added.
- The largest MacroGenics seller in Q4 2018 was EcoR1 Capital, an estimated $31.8M sold.
Based on aggregated 13F filings for Q4 2018.